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Iliac artery stenting combined with open femoral
endarterectomy is as effective as open surgical
reconstruction for severe iliac and common
femoral occlusive disease
Michele Piazza, MD,a Joseph J. Ricotta II, MD,a Thomas C. Bower, MD,a Manju Kalra, MBBS,a
Audra A. Duncan, MD,a Stephen Cha, MS,b and Peter Gloviczki, MD,a Rochester, Minn
Purpose: To compare outcomes of hybrid repair (HR) combining iliac artery stenting and open common femoral
endarterectomy (CFE) with open aortoiliac and femoral reconstruction (OR) in patients with extensive iliac and common
femoral occlusive disease (IFOD).
Methods: Between 1998 and 2008, 92 patients (164 limbs) underwent OR and 70 (84 limbs) underwent HR. All patients
underwent concomitant CFE. Thirty-day mortality and morbidity, long-term patency, procedurally related limb salvage,
and overall survival were analyzed after stratification by iliac TransAtlantic InterSociety Consensus (TASC) classification
into TASC A/B and TASC C/D.
Results:HRpatients were older for both TASC groups (A/B, P .02; C/D, P .01) and had higher Society for Vascular
Surgery (SVS) cardiac comorbidity scores (A/B, P  .01; C/D, P < .001) compared with OR. Technical success was
>99% in both groups. An increase in the ankle-brachial index after the procedure was significantly higher in OR patients
(0.49 0.28) with TASC A/B lesions than HR (0.22 0.18, P .031). Hospital and intensive care unit (ICU) lengths
of stay were 3.9 days for HR patients in TASC C/D vs 9.4 days for OR patients (P  .005). Comparing HR and OR,
30-day morbidity (3% vs 5%, P  .55) and mortality (1.1% vs 1.4%, P  .85) were equivalent. Primary patency of HR vs
OR at 3 years was similar (91% vs 97%, P  .29) and was maintained after stratification by TASC A/B (89% vs 100%,
P  .38) and TASC C/D (95% vs 97%, P  .54). Multivariate analysis for patency indicated that major tissue loss
(Rutherford class 6) at presentation in the HR group was predictive of decreased long-term patency (P  .02). Limb
salvage at 3 years was 100% in both groups. Overall survival was 74% for OR vs 40% for HR (P  .007).
Conclusion: IFOD can be treated usingHRwith similar early and long-term efficacy vs OR. HR patients with TASC C/D
lesions experienced a shorter ICU and hospital stay than OR patients. HR should be considered for all patients with
IFOD regardless the severity of TASC classification, particularly in those with high surgical risk. When deciding between
HR and OR, one must consider that major tissue loss at presentation is a negative predictor of long-term patency in
patients undergoing HR. (J Vasc Surg 2011;54:402-11.)
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mIliac and common femoral artery (CFA) occlusive dis-
ease (IFOD) can often manifest in a debilitating condition
for patients and be challenging to manage because multiple
levels of the arterial tree are involved. The gold standard for
treatment of extensive occlusive disease of the iliac segment
is open surgical reconstruction with aortobifemoral (ABF)
or iliofemoral (IF) bypass, depending on the extent and
laterality of the lesions. Excellent durability has been dem-
onstrated for these open surgical reconstructions; however,
they require a laparotomy or flank incision and often aortic
cross-clamping, which are associated with increased mor-
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402idity and can be challenging, particularly in patients at
igh operative risk.1
In the last decade, less invasive endovascular proce-
ures such as iliac balloon percutaneous transluminal an-
ioplasty (PTA) and stenting have gained popularity as an
lternative to open surgery for the treatment of focal iliac
cclusive disease. Rapid evolution of techniques and mate-
ials has also allowed operators to treat more extensive and
evere iliac lesions.
According to the recently modified guidelines from the
rans-Atlantic InterSociety Consensus (TASC) II document,
ndovascular management is preferred to open surgery in the
resence of TASC A and B iliac lesions, and surgical recon-
truction is the recommended treatment for TASC C and D
esions in good-risk patients.2 Femoral endarterectomy for
cclusive disease of the CFA has been standard practice for
50 years.3,4 Patch arterioplasty with autogenous vein, pros-
hetic, ormore recently, prosthetic or bovine pericardial patch
aterial is generally used, providing satisfactory results with
ow surgical risk. In the presence of severe IFOD, hybrid
epair (HR) combining endovascular iliac stenting and com-
on femoral endarterectomy (CFE), may represent an alter-
ative to open aortoiliofemoral surgical reconstruction (OR),
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Volume 54, Number 2 Piazza et al 403with shorter length of hospitalization and less resource utili-
zation.5
The purpose of this study was to review our contem-
porary experience treating severe chronic IFOD with HR
and to compare the results with OR procedures. Particular
attention was given to periprocedural safety, technical out-
comes, long-term procedural durability for both open and
hybrid treatments, and patient survival. The most current
standards were used to define the different variables.
METHODS
This study was approved by the Institutional Review
Board of Mayo Clinic, Rochester, Minnesota. Informed
consent requirements were waived for this study.
Patients. A retrospective review was performed of all
consecutive patients admitted at the Mayo Clinic who
underwent HR or OR for severe chronic IFOD between
January 1, 1998, and December 31, 2008. TASC A or B
iliac disease was present in 48 patients (59 limbs) who were
included in the TASC A/B group, and 114 patients (189
limbs) had iliac TASC C or D disease and were included in
the TASC C/D group. During this time, 92 patients
underwent ORwith aortobifemoral (n 72) or iliofemoral
bypass (n  20, all unilateral) supplying blood flow to 164
limbs, and 70 patients underwentHR supplying blood flow
to 84 limbs (14 bilateral and 56 monolateral).
Stenting in the HR group was selectively performed in
the common iliac artery in 20 limbs (23.8%), external iliac
artery in 41 limbs (48.8%), and combined common and
external iliac artery in 23 limbs (27.4%). Demographics,
perioperative outcomes, and long-term follow-up data
were obtained through review of patient medical records,
including diagnostic invasive and noninvasive studies.
Inclusion and exclusion criteria. Patients in the OR
group who required ABF or IF bypass were included in this
study only if simultaneous CFE was performed on at least
one limb side. The study excluded patients with aortic
thrombosis, concomitant abdominal aortic or iliac aneu-
rysms, concomitant visceral artery revascularization, and
acute limb ischemia, along with patients aged40 years of
age with traumatic etiology for their disease from high-
performance sport (competitive cyclists).
In the HR group, all patients with both focal and
extensive iliac obstructive disease that underwent endovas-
cular iliac revascularization were included only if concom-
itant CFE was performed.
Treatment and definitions. In recent years at our
institution, HR has surpassed OR as the preferred treat-
ment for severe chronic IFOD. In the first 3 years of this
experience,90% of the revascularizations were performed
with OR. With improvement in techniques and materials
for endovascular procedures, HR has becomemore popular
especially for the treatment of high-risk patients with bilat-
eral or extensive iliac disease. Most of the HRs have been
performed in the last 6 years, withHR overtakingOR in the
last 3 years (78% vs 22%).
Patient demographics, clinical characteristics, radio-
logic, and operative data were obtained from the medical aecords. Hyperlipidemia was defined as patients with this
ocumented diagnosis or who were being treated for ele-
ated plasma lipids (usually with statins), or both. Renal
nsufficiency was defined as serum creatinine concentration
f 1.5 mg/dL.
Operative comorbidity risk was evaluated using the
ociety for Vascular Surgery (SVS) comorbidity grading
ystem,6 the American Society of Anesthesiologists (ASA)
core, and the Eagle criteria.7 Chronic limb ischemia was
lassified by symptoms at presentation using SVS/Ameri-
an Association for Vascular Surgery reporting standards
AAVS).8 The TASC classification2 was used to evaluate
liac and femoropopliteal occlusive disease extent in both
roups of patients. CFA occlusive disease was classified
ccording to computed tomography (CT) imaging as mild
50% stenosis), moderate (50% to 74% stenosis), or severe
75% to 99% stenosis) and occlusion.
All patients suspected of having CFA occlusive disease
y physical examination, noninvasive vascular laboratory
tudies, or duplex ultrasound imaging underwent CT scan
r CT angiogram for confirmation. The severity of stenosis
nd therefore the decision to perform CFE was based on
T imaging. CFE was performed when the femoral artery
tenosis was50%. CFA runoff was evaluated according to
VS/AAVS reporting standards in a decimal scoring system
hat ranges from 1 to 2 (patent) to9 (minimal/absent).8
Early outcomes (30 days from surgery) were evalu-
ted comparing periprocedural data, associated morbility,
nd mortality between the two groups. Criteria for evalu-
ting improvement after surgery were the absolute differ-
nces between the preoperative and postoperative ankle
rachial index (ABI) and the SVS/AAVS postoperative
linical improvement score.8
Average length of follow-up was 3.54 years (range, 30
ays-11.5 years), with a mean follow-up of 3.9 years for OR
4.41  3.26 years) and 2.2 years for HR (1.54  1.56
ears). The follow-up visit consisted of physical examina-
ion, ABI measurement, and duplex scan of the bypass graft
r iliac stent as well as the CFE site at 3, 6, and 12 months
nd yearly thereafter. If the follow-up visit was concerning
or graft stent or CFE restenosis, a CT angiogram was
btained for further evaluation.
Primary, primary assisted, and secondary patencies
ere determined in concordance with the SVS/AAVS
uidelines8 after stratification by TASC category A/B and
/D. Loss of patency was determined by the loss of previ-
usly palpable pulses, patients presenting with recurrent
ymptoms, a drop in ABI0.15, Doppler ultrasound find-
ngs of occlusion, or a combination of these. Failures un-
erwent repeat angiography. Deaths were verified by the
ayo Clinic Registration database.
Operative technique. OR and HR were both per-
ormed by members of the Mayo Clinic Department of
ascular and Endovascular Surgery. The aortobifemoral
rocedures were preferentially performed through a trans-
eritoneal approach with a bifurcated Dacron prosthesis
utured in an end-to-end or end-to-side fashion proximally
nd end-to-side distally. Concomitant CFE was performed
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August 2011404 Piazza et alin all the considered population except for 16 limbs of the
173 limbs in the TASC C/D group that underwent OR for
bilateral iliac revascularization with ABF bypass and CFE
on only one side for significant (50%) unilateral femoral
artery disease. CFE was not performed in the other limb
because the femoral stenosis did not meet criteria (50%
stenosis); however, occlusive disease was present and a large
spatulated anastomosis was performed to the CFA on that
side in these limbs. Associated profundoplasty was per-
formed when the deep femoral artery had50% stenosis by
preoperative CT scan, or at the time of operation if the
orifice was unable to accept a 3-mm dilator.
In the HR group, endovascular iliac PTA and stenting
procedures were performed in a dedicated endovascular
suite after completion of the CFE and patch angioplasty.
Once the CFE was performed, the proximal and distal ends
were secured with tacking sutures and the femoral artery
was closed with patch angioplasty using a standard elliptic
bovine pericardial, Dacron, or rarely, venous patch. Upon
completion of patch closure, blood flow was restored to the
leg.
Access to the iliac arteries was performed through a
center patch puncture with an 18-gauge needle and subse-
quent placement of a 7F sheath over the wire and through
the center of the patch. Our preference is to perform the
endarterectomy and patch before iliac stenting because it
can be difficult to access the true lumen in a severely
stenotic or occluded CFA.
Once the endarterectomy is performed, it is important
to tack down the proximal end to avoid raising a dissection
flap with needle entry through the patch. In addition,
placing stents into the distal iliac arteries before CFE and
patch often precludes the ability to use a clamp for proximal
control of inflow into the CFA because of concern over
crushing the stent and frequently necessitates placement of
a balloon for inflow control, which can make the CFE and
patch closure more cumbersome.We prefer to avoid this by
performing the CFE and patch first, followed by stenting of
the iliac arteries.
Primary stenting of iliac stenosis was predominantly
performed with self-expanding nitinol stents, except in
cases of common iliac artery orificial lesions, where balloon-
expandable stents were used. Some long occlusive seg-
ments were treated with stent graft placement after iliac
recanalization. For lesions involving the external iliac ar-
tery, our practice is to extend the treatment zone, with PTA
or stenting down to the superior border of the inguinal
ligament if necessary, with great care not to cross the
inguinal ligament to avoid kinking of the stent with hip and
waist flexion.
Statistical analysis. Mean and standard deviation of
the ABI before and after surgery between the two proce-
dures were compared by two-sample t test. The Pearson,
2, and Fisher exact test was used for analysis of categoric
variables. Kaplan-Meier survival curves for primary patency,
primary assisted patency, secondary patency, and death
were estimated, and the log-rank P value was used to
compare two procedures. The multivariate Cox propor- 8ional hazard model was used to identify independent
redictors of mortality and patency. Univariate analysis was
dopted to stratify patency by TASC aortoiliac classifica-
ion. A value of P  .05 was used to determinate statistical
ignificance.
ESULTS
Patients undergoing OR were aged 61  14 years vs
8 12 years for HR (P .003), and this was maintained
ven after stratification by TASC category (A/B, P  .02;
/D, P  .01). Age 60 years at the time of surgery was
ignificantly higher in the OR group than in the HR group
or TASC A/B lesions (P  .004), and SVS comorbidity
core was significantly higher for patients who underwent
R than OR (3.21 1.8 vs 2.46 1.5, P .006) in both
ASC A/B and TASC C/D groups.
Perioperative risk score assessment was greater for
ASCC/D patients who underwentHR, with significantly
igher Eagle criteria score (P  .004), mean ASA score
P  .048), and SVS sum comorbidity score (P  .038)
ompared with OR. Patient characteristics and risk scores
re stratified by TASC A/B and TASC C/D and reported
n Table I.
Most patients in both groups presented with disabling
laudication (74.4% OR and 60% HR), which held true
fter separation by TASC grade. However, tissue loss at
resentation was higher in the HR group than in the OR
roup for TASC C/D lesions (26% HR and 10% OR, P 
04). HR patients were more likely to be categorized as
ASC A/B (59%), whereas OR patients were more com-
only TASC C/D (94.5%). The overall rate of severe
75%) stenosis of the CFA was 98% in HR group vs 64%
n OR (P  .001), and this was maintained even after
rouping by TASC grade A/B (P  .001) and C/D (P 
002). No significant differences in CFA runoff or femoro-
opliteal TASC classification between the two groups and
fter stratification by TASC category were identified
Table II).
Patients undergoing HR had significantly shorter in-
ensive care unit (0.14 vs 2 days, P  .004) and hospital
tays (3.9 vs 8.3 days, P  .005) compared with the OR
roup for TASC C/D, but interestingly, no differences
ere noted for TASC A/B (Table III).
HR was more often associated with deep femoral artery
evascularization for both TASC A/B and C/D lesions
P .001 for both categories), and80% of iliac endovas-
ular procedures were performed using PTA and stenting,
ith a mean number of 1.12 stents per patient for TASC
/B and 1.42 for TASC C/D. Stents were placed in the
ommon iliac artery in 20 limbs (23.8%), the external iliac
rtery in 41 (48.8%), and combined common and external
liac artery in 23 (27.4%). The distribution in stent place-
ent according to TASC grade is included in Table III. No
ignificant difference in long-term patency was identified
fter stratification for site of stent placement (external iliac
rtery, 88.1%; common iliac artery, 94.4%; and both,
5.7%; P .97) and type of stent used (uncovered stent in
8.3% and stent graft in 100% P  .47). The incidence of
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Volume 54, Number 2 Piazza et al 405associated outflow revascularization procedures in the
femoral-popliteal segment was not significantly different
between OR and HR group (3% and 5%, respectively;
P  .42).
The overall technical success was 100% for OR and 99%
for HR. Postoperatively, the mean ABI increased signifi-
cantly from 0.48 to 0.77 in the OR patients and from 0.52
to 0.77 in the HR patients (P  .001 for both groups).
After stratification by TASC, only TASC A/B patients who
underwent OR had a significant increase in ABI compared
with TASC A/B patients who underwent HR (P  .031).
There was no difference in increase in ABI betweenOR and
HR in patients with TASC C/D lesions. Evaluation of
lower limb clinical status at 30 days from surgery demon-
strated similar improvement for OR (96% vs 91%) of TASC
C/D lesions, although this difference was not statistically
significant (P .06). Major medical postoperative compli-
cations occurred with similar incidence in both groups,
Table I. Demographics, cardiovascular risk factors, and pe
common femoral occlusive disease treated with open (OR)
InterSociety Consensus (TASC) lesions
Variablea
TASC A-B (n  48)
OR (n  7) HR (n  41
Demographics
Age, years 53  12.5 66.7  13.
Age 60 years 5 (71) 8 (20)
Male gender 5 (71) 27 (66)
Cardiovascular risk factors
BMI, kg/m2 25.6  4.4 29  7.3
Hypertension 6 (86) 38 (93)
Hyperlipidemia 5 (71) 29 (71)
Diabetes 0 9 (22)
Smokingc 4 (57) 36 (88)
Coronary artery disease 3 (43) 28 (68)
NYHA class III-IV 0 1 (2.4)
Renal insufficiency 1 (14) 9 (22)
Dialysis 0 2 (5)
COPD 2 (29) 11 (27)
Home oxygen therapy 0 2 (5)
History of
TIA 1 (14) 3 (7)
Stroke 0 (0) 4 (10)
CEA 1 (14) 4 (10)
CABG 4 (57) 10 (24)
Endoiliac procedured 1 (14) 3 (7)
Peri-op risk assessment
Eagle criteria4,5e 0 3 (7)
ASA score 2.71  0.49 2.95  0.3
SVS cardiac score 0.43  0.79 3.65  3.4
SVS pulmonary score 0.71  1.25 0.89  1.8
SVS renal score 0.29  0.49 0.7  1.5
SVS sum score 4.25  1.50 8.7  5.1
ASA, American Society of Anesthesiologists; BMI, body mass index; CAB
obstructive pulmonary disease; NYHA, New York Heart Association; SVS, S
aData are presented as mean  standard deviation and number (%).
bStatistically significant.
cIncludes current and former smokers.
dPercutaneous transluminal angioplasty or percutaneous transluminal angio
eEagle criteria4,5  four or five coexisting clinical characteristics: age 70 ywith an overall rate of 5% in the OR group and 3% in the sR group (P .55). Surgically related complications were
ot statistically different between either group, and mortal-
ty at 30 days was 1% for both groups, regardless of TASC
rade (Table IV). Limb salvage related to the iliofemoral
evascularization was 100% for both groups.
There were no statistically significant differences in
verall primary (91% vs 98%, P .3), assisted primary (93%
s 98%, P  .5), or secondary patency (97% vs 100%, P 
11) at 3 years between HR and OR. This held true even
fter stratifying for iliac TASC A/B, which had a primary
atency of 89% vs 100% (P .38) and a secondary patency
f 95% vs 100% (P .54), and TASC D lesions, which had
primary patency of 95% vs 97% (P  .5) and secondary
atency of 100% for both groups (P  .79; Figs 1 and 2).
We carefully explored multivariate modeling for pa-
ency, which demonstrated that the only negative predictor
or patency was major tissue loss (Rutherford class 6) at
resentation in patients undergoing HR (Table V). Severe
erative risk assessment in 162 patients with iliac and
ybrid (HR) revascularization stratified by TransAtlantic
P
TASC C-D (n  114)
POR (n  85) HR (n  29)
.02b 62  13.8 69.3  10.1 .01b
.004b 34 (40) 6 (21) .06
.77 58 (68) 19 (66) .79
.28 27.5  5.5 27.4  8.6 .99
.54 77 (91) 27 (93) .68
.97 57 (67) 18 (62) .62
.17 25 (29) 7 (24) .59
.04b 80 (95) 23 (82) .027b
.19 50 (60) 19 (66) .57
.15 4 (4.7) 4 (13) .047
.64 11 (13) 7 (24) .15
.55 1 (1) 2 (7) .1
.92 19 (22) 4 (14) .32
.55 0 2 (7) .015b
.54 9 (11) 0 (0) .07
.39 1 (1) 1 (3) .42
.72 16 (19) 3 (10) .29
.08 8 (9) 12 (41) .001b
.54 5 (6) 5 (17) .06
.46 1 (1) 4 (14) .004b
.12 2.65  0.49 2.92  0.39 .048b
.019b 0.41  0.62 3.35  3.11 .001b
.81 0.35  0.79 0.92  1.90 .25
.48 0.18  0.39 0.81  1.70 .14
.09 5  2.97 8.67  5.28 .038b
ronary artery bypass graft; CEA, carotid endarterectomy; COPD, chronic
for Vascular Surgery; TIA, transient ischemic attack.
and stenting.
iabetes mellitus, myocardial infarction, angina, congestive heart failure.riop
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)
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August 2011406 Piazza et allong-term patency. Interestingly, even though associated
profundoplasty was significantly more often performed
during HR, this was not a positive predictor of patency in
Table II. Preoperative clinical and anatomical spectrum fo
revascularization for chronic iliofemoral disease stratified b
and C-D
Variablea
TASC A-B (59 limbs)
OR (n  9) HR (n  50)
Rutherford class
2-3 7 (77) 38 (76)
4 0 4 (8)
5-6 2 (22) 8 (16)
CFA grade of stenosis
Minimal (50%) . . . 0
Moderate (50%-74%) 2 (22) 1 (2)
High (75%-99%) 5 (55) 48 (96)
Occlusion 2 (22) 1 (2)
CFA runoff
Patent1,2 6 (66) 30 (60)
Reduced3-5 1 (1) 15 (30)
Severely reduced6-8 2 (22) 4 (8)
Minimal/absent (9) 0 1 (2)
TASC class fem-pop
A-B 7 (78) 34 (69)
C–D 2 (22) 16 (31)
CFA, Common femoral artery.
aData are expressed as number (%).
bStatistically significant.
Table III. General operative and procedural information b
by TransAtlantic InterSociety Consensus (TASC) lesions A
Variablea
TASC A-B
OR HR
(Pts  7) (Pts  41
Operative data
General anesthesia 7 (100) 36 (87)
Transfusion, mL 240  320.6 133.9  37
Length of stay, days
Intensive care unit 0.14  0.38 0.22  0.
Hospital 5.57  3.31 4.93  5.
(Limbs  9) (Limbs 
Procedural data
Native CFA . . . . . .
CFE 9 (100) 50 (100
CFE  patch 0 49 (99)
CFE  profundoplasty 1 (14) 29 (58)
Endovascular target
CIA . . . 16 (32)
EIA . . . 23 (46)
CIA-EIA . . . 11 (22)
Mean number of stents . . . 1.12  0.
PTA alone . . . 6 (12)
PTA  stent . . . 34 (68)
PTA  stent graft . . . 10 (20)
Associate outflow procedure 0 2 (4)
CFA, Common femoral artery; CIA, common iliac artery; EIA, external ilia
aData are expressed as mean  standard deviation or number (%).
bStatistically significant.the multivariate analysis. wOverall survival was significantly higher for patients
ndergoing OR than for patients undergoing HR (88% vs
3%, P .007), and this difference was particularly evident
8 limbs undergoing open (OR) or hybrid (HR)
nsAtlantic InterSociety Consensus (TASC) lesions A-B
TASC C-D (189 limbs)
P OR (n  155) HR (n  34) P
.64 .03b
.91 115 (74) 22 (65) .26
.38 24 (15) 3 (9) .31
.65 16 (10) 9 (26) .04b
.001b .002b
16 (10) 0
40 (26) 1 (3)
65 (42) 25 (73)
34 (22) 8 (23)
.43 .92
46 (30) 4 (12)
50 (32) 13 (38)
46 (30) 12 (35)
13 (8) 5 (15)
.56 .17
84 (54) 14 (41)
71 (46) 20 (59)
en repair (OR) and hybrid repair (HR) patients stratified
d C-D
P
TASC C-D
P
OR HR
(Pts  85) (Pts  29)
0.33 85 (100) 29 (100) —
NS 370  526.6 195  304 NS
0.84 2  5.91 0.14  0.35 .04b
0.77 8.39  8.13 3.93  3.34 .005b
(Limbs  155) (Limbs  34)
. . . 16 (10) . . . . . .
. . . 139 (90) 34 (100) .64
.001b 10 (6.45) 34 (100) .001b
.017b 53 (34) 20 (59) .034b
. . . . . . 4 (12) . . .
. . . . . . 18 (53) . . .
. . . . . . 12 (35) . . .
. . . . . . 1.42  0.61 . . .
. . . . . . 2 (6) . . .
. . . . . . 27 (79) . . .
. . . . . . 5 (15) . . .
.59 8 (42) 2 (6) .001b
ry; PTA, percutaneous transluminal angioplasty.r 24
y Tray op
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Volume 54, Number 2 Piazza et al 40770%, P  .016; Fig 3). However, this may represent a bias
related to the low number of patients (n  7) in the OR
group.
Multivariate analysis for survival was performed to eval-
uate its association with patient demographics, risk factors,
risk score, and operative characteristics. Although the HR
group had a higher mortality rate (hazard ratio, 1.965),
multivariate analysis did not demonstrate HR to be an
independent risk factor for death (P  .18; Table V).
Rutherford classes 5 (minor tissue loss) and 6 (major tissue
loss) at presentation, ASA score 3 to 4, and an SVS score
15 were negative predictors of survival, with hazard ratios
of 2.3 (P  .02), 4.5 (P  .02), and 3.0 (P  .01),
respectively. Interestingly, age60 at the time of interven-
tion did not have an effect on mortality (P  .79).
DISCUSSION
In recent years, we have adopted a preferred strategy of
HR with combined CFE and iliac artery stenting rather
than traditional ORwith aortofemoral or iliofemoral bypass
for the treatment of severe iliac and CFA occlusive disease.
This study was constructed to investigate whether HR can
be performed with equivalent safety, efficacy, and durability
as OR.
The treatment of IFOD with HR has obvious appeal.
Among the factors that have helped popularize HR are
Table IV. Early outcomes (30 days from surgery) in 16
disease treated with open (OR) or hybrid (HR) revasculari
(TASC) A-B and C-D lesions
Outcome (30 days)a
TASC A-B
OR H
(Pts  7) (Pts
Medical outcomes
Major cardiacb 0 1 (
Respiratory failurec 0
Dialysis 0
Death 0
(Limbs  9) (Limb
Surgical outcomes
Technical success 9 (100) 50 (
Ankle-brachial index
Before 0.45  0.38 0.51
After 0.9  0.17 0.76
Increase 0.49  0.28 0.22
Clinical improvement 9 (100) 49 (
Limb ischemia/thrombosis 0
Early additional reinterventione 0 1 (
Inguinal hematoma 0 1 (
Wound infection 1 (11)
Lymph leak 0 1 (
Laparotomy wound complication 0
aContinuous data are shown as mean  standard deviation, categoric data a
bIntraoperative or perioperative major cardiologic event that required
transluminal angioplasty, pacemaker implantation).
cPulmonary embolism or severe respiratory distress.
dStatistically significant.
eFasciotomy or additional distal revascularization.decreased hospital and intensive care unit length of stay, cess surgical morbidity, and more recently, patient prefer-
nce dictating a minimally invasive approach. When iliac
isease is associated with femoral obstructive lesions, the
ultilevel presentation could suggest a more virulent and
dvanced atherosclerotic process with concomitant in-
reased vascular systemic comorbidity compared with a
atient with isolated iliac disease. Despite the nonrandom-
zed nature of this study, the two groups undergoingOR or
R were well matched for risk factors, TASC grade, and
ther salient clinical variables.
The patients in this series who underwent HR were
lder, had higher comorbidity risk (higher cardiac SVS
core), and more often presented with tissue loss than did
he OR patients. These results may be explained by the
urgeons’ preference to treat higher-risk patients with HR
ather than with OR. The 30-day mortality and morbidity
ates were similar between the two groups; however, overall
urvival at 3 years was significantly higher for patients who
nderwent OR compared with HR. We used the multivar-
ate model to investigate whether the reduced long-term
urvival with HR was related to the procedure itself. This
nalysis demonstrated that HR was not an independent
redictor of death, but that high SVS comorbidity and ASA
cores were predictive of reduced long-term survival, as was
utherford classes 5 and 6. The decreased survival in pa-
ients undergoing HR was likely because they had more
ients with acute iliac and common femoral occlusive
n stratified by TransAtlantic InterSociety Consensus
P
TASC C–D
P
OR HR
) (Pts  85) (Pts  29)
.68 2 (2.3) 1 (3.4) .75
2 (2.3) 0 .40
1 (1.1) 0 .56
1 (1.1) 1 (3.4) .42
0) (Limbs  155) (Limbs  34)
— 155 (100) 33 (99) .18
2 .55 0.49  0.23 0.47  0.18 .55
4 .32 0.76  0.22 0.8  0.23 .5
8 .031d 0.28  0.26 0.29  0.22 .93
.67 149 (96) 30 (91) .06
— 1 (0.6) 1 (3) .24
.67 2 1 (3) .49
.67 1 (0.6) 1 (3) .24
.15 1 (0.6) 1 (3) .24
.67 3 (1.9) 1 (3) .71
. . . 1 (0.6) . . . . . .
wn as number (%).
ntion (cardiac massage, coronary artery bypass grafting, percutaneous2 pat
zatio
R
 41
2.4)
0
0
0
s  5
100)
 0.2
 0.2
 0.1
99)
0
2)
2)
0
2)
0
re sho
interveomorbidities and an overall worsened medical condition
r
i
i
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August 2011408 Piazza et althan those who underwent OR, but their deaths were not
related to the hybrid procedure itself. Consequently, HR
could be a valid alternative to OR for high-risk patients,
Fig 1. Kaplan-Meier estimates of primary (solid line) an
open repair (OR, blue line) or hybrid repair (HR, red lin
iliofemoral occlusive disease.
Fig 2. Kaplan-Meier estimates of primary (solid line) an
open repair (OR, blue line) or hybrid repair (HR, red lin
iliofemoral occlusive disease.eliminating the invasiveness and physiologic stress that tesult from aortic cross-clamping, as well as shortening
ntensive care unit and hospital stays and potentially reduc-
ng perioperative morbidity. Treating these high-risk pa-
ondary patency (dotted line) in patients who underwent
TransAtlantic InterSociety Consensus (TASC) A and B
ondary patency (dotted line) in patients who underwent
TransAtlantic InterSociety Consensus (TASC) C and Dd sec
e) ford sec
e) forients with HR instead of OR may be a reason for the
c
b
p
m
g
C
t
solid
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Volume 54, Number 2 Piazza et al 409reduced 30-day morbidity and mortality observed for OR
in this study, in contrast to a large meta-analysis that
reported an aggregate operative mortality of 3.3% and
postoperative morbidity of 8.3% for aortobifemoral by-
pass.1
The TASC classification provides a framework to assess
the treatment of aortoiliac lesions by stratifying lesion
Fig 3. Kaplan-Meier estimates of survival in open repair
TransAtlantic InterSociety Consensus (TASC) A and B (
Table V. Final model of multivariate analysis for mortality
occlusive disease
Variable HR
Mortality
Hybrid repair 1.965
Age 60 0.894
Rutherford 5-6 2.300
ASA 3-4 4.539
SVS sum score 15 3.005
Patency
Hybrid repair 2.269
TASC aortoiliac C 0.557
TASC aortoiliac D 0.511
CFA stenosis 74% 0.643
CFA stenosis 75% 0.651
Profundoplasty 0.560
Rutherford class
5 0.433
6  hybrid repair 10.801
ASA, American Society of Anesthesiologists; CI, confidence limit; CFA, com
TransAtlantic InterSociety Consensus.
aStatistically significant.length and morphology.2 In this series, aortoiliac TASC nlassification and severity of CFA disease were different
etween the two groups, with HR group having mostly
atients with TASC A/B lesions and OR having patients
ostly TASC C/D lesions. In addition, HR patients had a
reater preponderance of severe stenosis or occlusion of the
FA compared with OR patients. Although this may bias
he results in this study, multivariate analysis for patency did
, blue line) and hybrid repair (HR, red line) stratified by
line) and C and D (dotted line) lesions.
patency in 162 patients with iliac and common femoral
5% CI Ratio limit P
0.734 5.261 .1788
0.383 2.085 .7948
1.135 4.658 .0207a
1.238 16.64 .0225a
1.239 7.288 .0150a
0.430 11.961 .3340
0.116 2.680 .4656
0.102 2.550 .4131
0.132 2.221 .5524
0.182 2.396 .6435
0.143 2.196 .4059
0.055 3.393 .4256
1.305 89.422 .0273a
femoral artery;HR, hazard ratio; SVS, Society for Vascular Surgery; TASC,(ORand
9
monot show any statistically significant difference for CFA
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August 2011410 Piazza et algrade of stenosis or iliac TASC classification between the
two groups.
The only negative predictor of patency was Rutherford
class 6 ischemia, suggesting that clinical presentation may
be a more accurate predictor of patency rather than the
specific location or severity of stenosis in the presence of
IFOD. In our study, patients with bilateral iliac TASCC/D
lesions were preferentially treated with OR and patients
with focal and unilateral iliac disease with associated severe
CFA occlusive disease were treated with HR. During the
last 3 years of this study, the number of patients with
bilateral TASC C/D lesions treated with HR increased
significantly, particularly for high-risk patients. This is a
reflection of advancement in techniques and materials, as
well as increased skill and comfort level of the operators. It
is important to note, however, that even in the presence of
concomitant CFA disease, the recommendations from the
TASC document can be applied.
A large body of literature has published outcomes after
AFB; however, most of the studies were performed in the
1970s and 1980s, before endovascular therapy gained pop-
ularity and widespread use. The most extensive review was
done by de Vries andHunink1 in 1997. Their meta-analysis
of 25 articles demonstrated that the overall 5-year patency
rate was 91% for patients with claudication and 87% for
patients with critical limb ischemia. More recent data9
reported an overall primary patency for ABF bypass of 93%
at 3 years and secondary patency of 97%, which are compa-
rable with the results in our study. In that study, multilevel
disease negatively affected durability of the procedure and
patient survival. On the other hand, Chang et al5 recently
reported primary patency for HR was approximately 75%,
with a secondary patency 98% at 3 years for TASC C/D
lesions.
In our series, primary patency at 3 years for HR was
higher and comparable with OR (97% vs 95%, P  .54).
This finding could be explained by the fact that only 40% of
patients in the HR group had TASC C/D iliac lesions,
compared with 94% in the OR group. However, when
stratifying for TASC C/D lesions, the primary patency for
HR (95%) was similar to that for OR (97%; P  .54). In
multivariate analysis, the only factor predictive of reduced
patency was Rutherford class 6 (major tissue loss) in HR,
indicating that perhaps clinical presentation is more impor-
tant than any other type of anatomic classification for
predicting long-term patency.
Another important determinant of long-term patency
after iliac endovascular treatment and CFE is the adequacy
of distal runoff of the CFA and femoral-popliteal segment.
Although in the multivariate model, associated profundo-
plasty and associate distal revascularization were not predic-
tive of increased patency, approximately 60% of HR proce-
dures were associated with profundoplasty, with similar
rates for TASC A/B and C/D lesions. Associated profun-
doplasty in the OR group was much lower, ranging from
14% for TASC A/B to 34% in TASC C/D. Additional
profundoplasty to the CFE in a patient with femoral-
popliteal disease could allow sufficient clinical improve- Fent and critical outflow to the lower extremity. Previ-
usly, treating deep femoral artery orificial lesions was
hown to lead to improvement in ABF bypass patency.10
imilarly, we can suppose that CFE and associated profun-
oplasty during HR, when indicated, may contribute to
mproved patency of the revascularized iliofemoral seg-
ent.
Our study has some limitations that are worthy of
ention. This was a retrospective, nonrandomized study in
referral center where many patients are from out-of-state
nd international locations; thus, consistent follow-up is
xtremely difficult. Nevertheless, most patients who re-
urned for follow-up at 1 year or less were also evaluated in
ubsequent years of follow-up, allowing assessment of
edium-term durability and survival at 3 years. Longer
ollow-up is ideal and may reveal data that could alter our
urrent conclusions.
In addition, 5 years of mean follow-up for the HR
roup was impossible because most of these procedures
ere performed after 2003. Mortality, however, was veri-
ed by using the Social Security Death index database,
hich permitted a robust survival analysis. The choice of
R vs HR was left to the discretion of the surgeon treating
he patient, leading to inherent biases. Clinical testing was
ot standardized and left to the discretion of the treating
hysician. Thus, all patients did not have noninvasive im-
ging along with physical examination findings at follow-
p. Ideally, a randomized controlled trial with a larger
umber of patients comparing OR and HR treatment for
IFOD is needed to minimize confounding variables. Un-
ortunately, with the preference for less invasive therapies
nd procedural selection based on operative risk, it may be
difficult trial to complete with regards to patient recruit-
ent and enrollment.
ONCLUSION
To our knowledge, no other published study has com-
ared the technique of CFE and iliac stenting with open
BF or IF bypass for the treatment of severe iliac and CFA
cclusive disease. The results of our study clearly confirm
hat IFOD can be treated using HR with shorter hospital-
zation and similar early- and long-term efficacy when
ompared with OR for both TASC A/B and TASC C/D
esions. HR should be considered for all patients with
FOD and particularly for those at high surgical risk. Long-
erm patency is similar in both groups regardless of severity
f TASC classification. However, when deciding between
R or OR, one must consider that major tissue loss at
resentation is a negative predictor of long-term patency in
atients undergoing HR.
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